On Thursday, Following U.S. Stocks were among the “Top Gainers”: Geron Corporation (NASDAQ:GERN), Mylan N.V. (NASDAQ:MYL), Insulet Company (NASDAQ:PODD), Sinclair Broadcast Group, Inc. (NASDAQ:SBGI)

Geron Corporation (NASDAQ:GERN), with shares inclined 5.60%, closed at $4.34.

Mylan NV(NASDAQ:MYL), with shares jumped 5.59%, settled at $62.30.

Insulet Corporation (NASDAQ:PODD), with shares climbed 5.40%, and closed at $34.77.

Sinclair Broadcast Group Inc (NASDAQ:SBGI), surged 5.37%, and closed at $28.07.

Latest NEWS regarding these Stocks are depicted underneath:

Geron Corporation (NASDAQ:GERN)

Formerly on Macrh 3, Geron Corporation (GERN), stated financial results for the fourth quarter and year ended December 31, 2014 and recent events.

Fourth Quarter 2014 Results:

Net loss for the fourth quarter of 2014 was $8.9 million, or $0.06 per share, contrast to $9.3 million, or $0.07 per share, for the comparable 2013 period. Proceeds for the fourth quarter of 2014 were $178,000 contrast to $225,000 for the comparable 2013 period. The corporation ended 2014 with $170.6 million in cash and investments, which comprised of receipt of an upfront payment of $35.0 million for the license rights granted by the corporation to Janssen Biotech, Inc. under the exclusive partnership and license contract reached between the parties in November 2014, which has been recorded as deferred proceed as of December 31, 2014.

Total operating expenses for the fourth quarter of 2014 were $9.2 million contrast to $9.5 million for the comparable 2013 period. Research and development expenses for the fourth quarter of 2014 were $4.4 million contrast to $5.1 million for the comparable 2013 period. General and administrative expenses for the fourth quarter of 2014 were $4.8 million contrast to $4.0 million for the comparable 2013 period. Operating expenses for the 2013 fourth quarter also comprised of restructuring charges of $430,000 in connection with the corporation`s decisions to discontinue its discovery research programs and close its research laboratory facility in 2013.

The decrease in research and development expenses for the fourth quarter of 2014, contrast to the same period in 2013, primarily reflects lower manufacturing costs for imetelstat drug product and reduced clinical trial expenses for the imetelstat trials in hematologic myeloid malignancies. The raise in general and administrative expenses for the fourth quarter of 2014, contrast to the same period in 2013, primarily reflects the net result of higher non-cash stock-based compensation expense, raised legal fees for the purported lawsuits filed against the corporation and transaction costs associated with the Partnership Contract with Janssen, partially offset by transaction costs associated with the closing of the stem cell divestiture transaction in October 2013.

Interest and other revenue for the fourth quarter of 2014 was $100,000 contrast to $115,000 for the comparable 2013 period. The decrease in interest and other revenue for the fourth quarter of 2014, contrast to the same period in 2013, primarily reflects the net result of a gain on the sale of excess laboratory equipment in connection with the closure of the corporation`s research laboratory facility in 2013, partially offset by higher interest revenue due to raised cash and investment balances with the receipt of $96.8 million in net cash proceeds from the underwritten public offering accomplished in February 2014.

Geron Corporation, a clinical stage biopharmaceutical corporation, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The corporation was founded in 1990 and is based in Menlo Park, California.

Mylan N.V. (NASDAQ:MYL)

Mylan N.V. (MYL), and Mylan Inc. declared the successful completion of the formerly declared consent solicitations regarding Mylan’s 3.750% Cash Convertible Notes due 2015, 7.875% Senior Notes due 2020, 3.125% Senior Notes due 2023, 1.800% Senior Notes due 2016, 2.600% Senior Notes due 2018, 1.350% Notes due 2016, 2.550% Notes due 2019, 4.200% Notes due 2023 and 5.400% Notes due 2043.

As formerly declared on Feb. 27, 2015, the Companies consummated the transactions contemplated by the Amended and Restated Business Transfer Contract and Plan of Merger, dated as of Nov. 4, 2014, between and among Abbott Laboratories, an Illinois corporation (“Abbott”), Mylan, the Parent, and Moon of PA Inc., a Pennsylvania corporation, as a result of which Mylan became a wholly-owned indirect partner of the Parent and the Parent attaind Abbott’s non-U.S. developed markets specialty and branded generics business. In addition, on Feb. 27, 2015, the Parent fully and unconditionally guaranteed each series of Notes.

The consent solicitations were made following the consent solicitation statement dated March 3, 2015. As of 5:00 p.m., New York City time, on March 11, 2015 (the “Expiration Date”), the consents were received from holders of a majority in aggregate principal amount of the outstanding Notes of each series to the adoption of the amendments described in the consent solicitation statement. The amendments modify the reporting covenants primarily to provide that, subject to certain conditions, the reports, information and other documents required to be filed with the Securities and Exchange Commission (“SEC”) and furnished to holders of the Notes following the indentures governing the Notes may, at the option of Mylan, be filed by and be those of any direct or indirect parent entity rather than Mylan.

Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide.

Insulet Company (NASDAQ:PODD)

The estimated date for earnings release for Insulet Corporation (PODD), is May 5 - May 11, 2015. In view of analyst’s opinion the mean recommendation for this stock in the current week is 2.5, while for the last week it was 2.4, just 0.1 changed. On February 27, 2015, Oppenheimer research firm downgraded the stock from “Outperform”, to “Perform”.

In the current month, the stock is recommended “Strong Buy” for the 5 Times, “Buy” for 3 Times, and “Hold” for 9 Times. On the other hand, during the last month, the stock was recommended “Strong Buy”, for 6 Times, “Buy” for 3 Times, “Hold” for 7 Times and “Underperform” for 1 Time.

Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. The corporation offers OmniPod Insulin Administration System (OmniPod System), which comprises of the OmniPod, a disposable insulin infusion device that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism, and batteries; and personal diabetes manager, a handheld wireless device.

Sinclair Broadcast Group, Inc. (NASDAQ:SBGI)

Formerly on February 18, Sinclair Broadcast Group, Inc. (SBGI), stated financial results for the three and twelve months ended December 31, 2014.

Three Months Ended December 31, 2014 Financial Results:

Total proceeds raised 43.5% to $613.8 million, as compared to $427.7 million in the preceding year period.

Operating revenue was $208.9 million, an raise of 102.4%, which comprises a net gain on asset dispositions of $37.8 million, as compared to operating revenue of $103.2 million in the preceding year period.

Net revenue attributable to the Corporation was $95.4 million, which comprises the net gain on asset dispositions and a loss on extinguishment of debt of $14.6 million, as compared to net revenue of $2.3 million in the preceding year period.

Diluted earnings per ordinary share were $0.98 as contrast to $0.02 in the preceding year period. Not including the loss on extinguishment of debt and the net gain on asset dispositions, diluted earnings per ordinary share would have been $0.84 for the fourth quarter of 2014.

Year Ended December 31, 2014 Financial Results:

• Total proceeds raised 45.0% to $1.977 billion, as compared to $1.363 billion in the preceding year period.
• Operating revenue was $494.7 million, an raise of 52.7%, which comprises a net gain on asset dispositions of $37.2 million, as compared to operating revenue of $324.0 million in the preceding year period.
• Net revenue attributable to the Corporation was $212.3 million, which comprises the net gain on asset dispositions and a loss on extinguishment of debt of $14.6 million, as compared to net revenue of $73.5 million in the preceding year period.
• Diluted earnings per ordinary share were $2.17 as contrast to $0.78 in the preceding year period. Not including the loss on extinguishment of debt and the net gain on asset dispositions, diluted earnings per ordinary share would have been $2.03 for the year ended December 31, 2014.

Sinclair Broadcast Group, Inc., a diversified television broadcasting corporation, owns and operates, programs, or provides sales services to television stations in the United States.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.